Can I read An Evaluation of Meropenem + Vaborbactam for the Treatment of Nosocomial Pneumonia on EtoBox?

An Evaluation of Meropenem + Vaborbactam for the Treatment of Nosocomial Pneumonia by Groft, Lauren M.; Claeys, Kimberly C.; Heil, Emily L. is a Medicine article available to read on EtoBox.

What is An Evaluation of Meropenem + Vaborbactam for the Treatment of Nosocomial Pneumonia about?

: Nosocomial pneumonias are the second most common healthcare-associated infections (HCAIs), often associated with the presence of , , , species, and species. Increasing use of carbapenems has led to an increase in the prevalence of carbapenem-resistant gram-negative organisms, such as carbapenem-resistant Enterobacterales (CRE), (CRPA), and (CRAB), limiting treatment options for patients at high-risk of multi-drug resistant (MDR) gram-negative pathogens. : The purpose of this review is to discuss the role of meropenem/vaborbactam, a beta-lactam combined with a novel non-beta-lactam cyclic boronic acid beta-lactamase inhibitor (BLI), for the treatment of nosocomial pneumonia based on its chemistry, pharmacokinetics/dynamics, microbiological spectrum of activity, mechanisms of resistance, safety, and clinical efficacy. : Currently, any utilization of meropenem/vaborbactam beyond its FDA-approved indication for complicated urinary tract infections is considered off-label use; however, based on the pulmonary penetration of meropenem/vaborbactam, it is highly likely to be a safe and effective alternative to more toxic agents, like aminoglycosides and polymixins, for targeted therapy in

Who reads An Evaluation of Meropenem + Vaborbactam for the Treatment of Nosocomial Pneumonia?

Author

Groft, Lauren M.; Claeys, Kimberly C.; Heil, Emily L.

Publisher

Informa plc; Informa UK (Taylor & Francis); Taylor & Francis; Informa UK Limited; Informa Healthcare (ISSN 1465-6566)

Published

2020

Language

EN

Field

Medicine (Health Sciences)